3′-sialyllactose targets cell surface protein, SIGLEC-3, and induces megakaryocyte differentiation and apoptosis by lipid raft-dependent endocytosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
3′-sialyllactose targets cell surface protein, SIGLEC-3, and induces megakaryocyte differentiation and apoptosis by lipid raft-dependent endocytosis
Authors
Keywords
-
Journal
GLYCOCONJUGATE JOURNAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-04
DOI
10.1007/s10719-019-09902-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
- (2018) Bruno C. Medeiros et al. Clinical Lymphoma Myeloma & Leukemia
- IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
- (2018) Yelena Kovtun et al. MOLECULAR CANCER THERAPEUTICS
- 3′-Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis
- (2017) Jimin Jeon et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Monosialyl Ganglioside GM3 Decreases Apolipoprotein B-100 Secretion in Liver Cells
- (2017) Hyunju Choi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Cyclic tensile stress of human annulus fibrosus cells induces MAPK activation: involvement in proinflammatory gene expression
- (2016) H. Pratsinis et al. OSTEOARTHRITIS AND CARTILAGE
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Functional role and mechanisms of sialyllactose and other sialylated milk oligosaccharides
- (2014) Sandra JM ten Bruggencate et al. NUTRITION REVIEWS
- The Ganglioside GM3 Is Associated with Cisplatin-Induced Apoptosis in Human Colon Cancer Cells
- (2014) Tae-Wook Chung et al. PLoS One
- Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway
- (2013) Huijuan Zhang et al. EXPERIMENTAL CELL RESEARCH
- Monosialic ganglioside GM3 specifically suppresses the monocyte adhesion to endothelial cells for inflammation
- (2013) Seok-Jo Kim et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
- (2013) Ana Griciuc et al. NEURON
- Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
- (2012) L. Ouyang et al. CELL PROLIFERATION
- Sialic Acid Utilization
- (2012) Norbert Sprenger et al. Advances in Nutrition
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- Involvement of ERK1/2, p38 and PI3K in megakaryocytic differentiation of K562 cells
- (2010) Isabel Conde et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response
- (2010) Anna I. Markowska et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sialic Acid Utilisation and Synthesis in the Neonatal Rat Revisited
- (2009) Peter I. Duncan et al. PLoS One
- The AP-2 transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene
- (2008) H.-J. Choi et al. GLYCOBIOLOGY
- Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2
- (2008) T.-W. Chung et al. GLYCOBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started